PAR 1.72% 28.5¢ paradigm biopharmaceuticals limited..

research reports and media, page-4100

  1. 3,988 Posts.
    lightbulb Created with Sketch. 1382
    Efficacy and safety of pentosan polysulfate sodium in people with symptomatic knee osteoarthritis and dyslipidaemia: protocol of the MaRVeL trial
    https://pubmed.ncbi.nlm.nih.gov/38777590/

    ACTRN12621000654853
    A Double-Blind, RandoMised, Placebo-Controlled Study to Assess the
    Efficacy and Safety of oRal deliVery of sodium Pentosan Polysulfate (PPS)
    compared to placebo in participants with symptomatic kneE osteoarthritis
    (OA) and dysLipidemia (MaRVeL Study)

    https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12621000654853

    Name
    Arthropharm Pty Ltd
    https://www.arthropharm.com.au/
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
28.5¢
Change
-0.005(1.72%)
Mkt cap ! $99.69M
Open High Low Value Volume
29.0¢ 29.0¢ 28.5¢ $34.79K 121.0K

Buyers (Bids)

No. Vol. Price($)
4 70181 28.0¢
 

Sellers (Offers)

Price($) Vol. No.
29.0¢ 10000 1
View Market Depth
Last trade - 14.42pm 24/07/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.